Gene therapy for lung cancer using tumor suppressor gene product as molecular target

以抑癌基因产物为分子靶点的肺癌基因治疗

• 批准号: 09670615
• 负责人: SHIMIZU Eiji
• 金额: $ 1.86万
• 依托单位: University of Tokushima
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1997
• 资助国家: 日本
• 起止时间: 1997 至 1998
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-09670615/
• 关键词: Lung cancer; Oncogene; Tumor suppressor gene; p16, rb; Gene therapy; Chemotherapy; Pleuritis carcinomatosa; Cisplatin; p16; RB; 抗癌剤感受性試験; コロニー形成試験

Treatment of inoperable lung cancer with pericarditis carcinomatosa consists of pleural administration of anticancer agents and/or inflammation-inducing agents, which have not improved the survival of the patients significantly because of poor local control and distant metastasis. Gene therapy for lung cancer using tumor suppressor gene including p53, rb, p16, an alternative of chemoimmunotherapy, which has recently developed in lung cancer, may improve the survival of the inoperable lung cancer patients with pleuritis carcinomatosa. In this study, we examined the basic and preclinical evaluation of rb and p16 in patients with carcinomatous pleural effusion. Under written informed consent, mononuclear cells were isolated from pleural effusion with seven patients with T4 status. Characteristics of patients include five males and two females/median age 72/6 adenocarcinomas and one small cell carcinoma. These samples formed 0-120 colonies per 200,000 mononuclear cells and five of seven patients were evaluable for antitumor

无法手术的肺癌伴癌性心包炎的治疗包括胸腔内给予抗癌剂和/或炎症诱导剂，但由于局部控制不佳和远处转移，这些方法并没有显着改善患者的生存率。使用抑癌基因（包括p53、rb、p16）对肺癌进行基因治疗，是最近在肺癌中发展起来的化学免疫疗法的替代方案，可能会提高不能手术的肺癌合并癌性胸膜炎患者的生存率。在本研究中，我们检查了癌性胸腔积液患者中 rb 和 p16 的基础和临床前评估。根据书面知情同意书，从 7 名 T4 状态患者的胸腔积液中分离出单核细胞。患者特征包括五名男性和两名女性/中位年龄 72/6 腺癌和一名小细胞癌。这些样本每 200,000 个单核细胞形成 0-120 个集落，七名患者中的五名可进行抗肿瘤评估

项目成果

Houchi H,et al: "Endothelin-1 stimulatese sodium-dependent calcium efflux from bovine adrenal chromaffin cells in culture." Int J Oncol. 12. 55-60 (1998)

Houchi H 等人：“Endothelin-1 刺激培养物中牛肾上腺嗜铬细胞的钠依赖性钙流出。”

Yoshimoto K,et al: "Infrequent detectable somatic mutations of the RET and glial cell line-derived neurotrophic factor(GDNF)genes in human pituitary adenomas." Endocrine J. (in press). (1999)

Yoshimoto K 等人：“人垂体腺瘤中 RET 和神经胶质细胞系源性神经营养因子 (GDNF) 基因的罕见体细胞突变。”

Yamamoto,T., Shimizu,E., Masuda,N., Takada,M.Sone,S.: "RB protein status and chemosensitivity in non-small cell lung cancers" Oncol.Rep.5. 447-451 (1997)

Yamamoto,T.、Shimizu,E.、Masuda,N.、Takada,M.Sone,S.：“非小细胞肺癌中的 RB 蛋白状态和化疗敏感性”Oncol.Rep.5。

Yoshida S,et al: "Synchronous small cell carcinoma and adenocarcinoma of the lung representing different retinoblastoma tumor suppressor protein status." Int J Clin Oncol. 3. 326-329 (1998)

Yoshida S 等人：“同步小细胞癌和肺腺癌代表不同的视网膜母细胞瘤肿瘤抑制蛋白状态。”

Houchi H et al: "Endothelin-1 stimulates sodium-dependent calcium efflux from bovine adrenal chromaffin cells in culture." Br J Pharmacol. 125. 55-60 (1998)

Houchi H 等人：“Endothelin-1 刺激培养物中牛肾上腺嗜铬细胞的钠依赖性钙流出。”